Picking the best mlops platform for regulated industries is not a cloud-vendor beauty contest — it is a compliance architecture decision that will be tested during audits, not just demos. The general capability trade-offs are covered in our enterprise MLOps platform comparison; everything below is what regulation adds on top of them. The platforms that win in healthcare, financial services, and pharma are the ones that make audit evidence a byproduct of normal ML work rather than a retroactive scramble. This piece breaks down what the major platforms actually deliver on the compliance dimensions that regulators examine.
What Regulated Industries Actually Require
The compliance bar differs by sector but converges on four hard requirements: full reproducibility, model explainability, integrated audit trails, and continuous monitoring with documented triggers.
Financial services now operates under revised interagency guidance issued April 17, 2026, when the Federal Reserve, FDIC, and OCC rescinded SR 11-7 and related guidance in favor of a risk-based, principles-driven framework. Models must be tiered by materiality, with proportionate controls at each tier. Lifecycle governance — development, validation, deployment, monitoring, and retirement — must form one defensible chain with complete lineage documentation. Challenger models and sensitivity tests must be versioned and reproducible.
Healthcare teams deploying FDA Software as a Medical Device (SaMD) must demonstrate that inference inputs, model weights, and outputs can be reconstructed after the fact. HIPAA audit logging requires timestamp, user identity, action, and PHI reference on every record access, with six-year minimum retention in tamper-evident (WORM) storage. The architecture constraint is significant: production data generally cannot transit vendor infrastructure without a signed Business Associate Agreement (BAA). The same constraint reaches back to the training set, which is why data versioning for production ML stops being optional in a regulated stack.
Pharma pipelines under 21 CFR Part 11 require electronic records and signatures that are trustworthy and equivalent to paper records. EU GMP Annex 11 adds similar requirements for European manufacturing sites. The FDA does not certify platforms as Part 11 compliant — the deploying organization bears that responsibility — but platform tooling determines how hard that validation exercise is.
Cross-sector: the EU AI Act classifies ML systems in healthcare, employment screening, credit scoring, and critical infrastructure as high-risk under Annex III, imposing conformity assessments, technical documentation, and human oversight requirements. Platforms with no European data-residency options create structural risk.
The underlying operational requirement, as one practitioner guide puts it: “every decision made during model development, validation, and deployment must be documented, reproducible, auditable, and in some cases pre-approved by regulators before the model can influence regulated decisions.”
Platform Breakdown: Who Wins on What
Databricks + MLflow + Unity Catalog is the strongest option for data-intensive financial services teams and organizations already on the lakehouse architecture. Unity Catalog provides centralized governance: fine-grained access control, cross-workspace lineage graphs that connect raw data through features to model versions and monitoring outputs, and automated evidence generation as a byproduct of normal development work. MLflow logs parameters, metrics, and artifacts for every training run. Model Registry stage transitions require human approval before promotion to production. That approval gate is the backbone of the registry patterns that hold up in production. Databricks holds HIPAA, HITRUST, SOC 2 Type II, and FedRAMP Moderate certifications, with FedRAMP High in progress. The weakness is onboarding cost: Unity Catalog governance requires deliberate schema design, and teams accustomed to ad-hoc notebooks see friction initially.
AWS SageMaker is the incumbent for healthcare teams that need HIPAA-eligible services inside AWS GovCloud, which provides regional isolation with FedRAMP High, DoD IL2/IL4, and HIPAA BAA coverage. SageMaker Pipelines and Model Registry support approval gates. The audit trail integrates with CloudTrail and CloudWatch Logs, which satisfies HIPAA’s structured logging requirement when configured correctly. For teams deploying quantized models via SageMaker JumpStart (INT8/GPTQ variants), the deployment metadata and endpoint configuration are versioned automatically. The gap is cross-platform lineage: SageMaker’s audit record is AWS-native and does not propagate cleanly to external governance tools without additional plumbing.
Azure Machine Learning is the pragmatic choice for pharma and life sciences organizations that are already Microsoft shops. Azure’s BAA covers the full service for HIPAA, and Microsoft Purview integrates with OneLake for cataloging and governance. The MLflow-compatible experiment tracking stores complete experimental context. A key differentiator: Azure ML’s model documentation framework — model cards covering intended use, data characteristics, evaluation results, and limitations — maps closely to what 21 CFR Part 11 validation packages require. Integration with Azure Active Directory and Purview allows organizations to enforce role-based promotion gates without building bespoke tooling.
Google Vertex AI has strong ML infrastructure (managed training, Pipelines, Feature Store) but the compliance certification portfolio is thinner than AWS or Azure for healthcare-specific requirements. Vertex AI is viable for EU-regulated organizations where Google Cloud’s EU data boundary commitments satisfy GDPR data-residency obligations, but teams requiring HIPAA BAA or FedRAMP High should verify current eligibility before committing.
Monitoring and Explainability: The Layer Auditors Examine
Platform selection does not end the compliance picture. Regulators in financial services specifically examine ongoing model behavior, not just deployment-time validation. The monitoring layer must track data drift (PSI — Population Stability Index, or KL divergence on input distributions), prediction drift (shift in output score distributions), and performance drift (degradation in AUC, recall@k, or calibration) with documented response thresholds.
Evidently AI, Arize AI, WhyLabs, and Fiddler AI integrate with all four major platforms and add the monitoring layer that platforms provide only partially. For teams shipping to sentryml.com-style observability stacks, these tools expose Prometheus-compatible metrics and OTel traces that feed existing alert pipelines. The practical architecture in most regulated shops: Databricks or SageMaker for training and registry, Evidently or Arize for production drift monitoring, and a model card store that links both together.
Explainability at inference time — SHAP values for tabular credit models, LIME for faster approximation, attention maps for transformer-based clinical NLP — must be generated on the same model version that was validated. If a deployed artifact diverges from the validated checksum, the SHAP explanation is no longer defensible to a regulator. The registry must be the single source of truth for which artifact is live.
Choosing by Sector
For financial services operating under the new 2026 interagency principles: Databricks with Unity Catalog provides the most mature lineage-to-audit-evidence pipeline, particularly for organizations with significant feature engineering and data transformation complexity.
For healthcare teams requiring HIPAA BAA with strong regional isolation: SageMaker inside GovCloud is the lowest-friction path, assuming the team is already AWS-aligned.
For pharma and life sciences running 21 CFR Part 11-governed workflows: Azure ML with Microsoft Purview and BAA coverage avoids the validation overhead of building bespoke audit trails.
For EU AI Act high-risk systems: any platform with documented EU data residency and a compliant data processing agreement is a prerequisite before evaluating MLOps features.
A caution on scope. Most compliance requirements written by risk functions cover every operational model, including scorecards, rules engines and optimisation models that never pass through an ML pipeline. A delivery platform cannot satisfy that on its own, which is the distinction drawn in ModelOps platform vs MLOps platform — and it is worth settling before the RFP, because it changes the shortlist. For the underlying delivery layer, weigh candidates with the MLOps Platform Selector, and check the feature layer separately in our feature store comparison, since lineage that stops at the training set fails an audit at the first question about inputs.
The regulatory posture of the EU AI Act, tracked by neuralwatch.org, is tightening through 2026 and 2027, with technical documentation and human oversight requirements coming into force for high-risk systems. Platform selection made now will be validated against those requirements. Building on a platform with weak lineage tooling means engineering compliance documentation manually later — at audit time, under time pressure, and at significant cost.
One control set is missing from most compliance checklists and increasingly asked about in third-party risk reviews: what happens to a model artifact between the registry and the endpoint. Artifact provenance, least-privilege inference and output handling are covered in secure ML model deployment best practices, and the evidence they produce is the same evidence a supervisory review will ask for.
One operational point that practitioners in this space consistently surface: the technical challenge in regulated deployments “is not primarily a machine learning problem” — it is an architectural problem around data control and compliance visibility. Platform tooling shapes how solvable that problem is.
